Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Christine Walsh to Neoplasm Staging

This is a "connection" page, showing publications Christine Walsh has written about Neoplasm Staging.

 
Connection Strength
 
 
 
0.756
 
  1. Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021; 16(6):e0252665.
    View in: PubMed
    Score: 0.126
  2. Penn CA, Wong MS, Walsh CS. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. JAMA Netw Open. 2020 12 01; 3(12):e2028620.
    View in: PubMed
    Score: 0.121
  3. Cohen JG, Prendergast E, Geddings JE, Walts AE, Agadjanian H, Hisada Y, Karlan BY, Mackman N, Walsh CS. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol. 2017 07; 146(1):146-152.
    View in: PubMed
    Score: 0.095
  4. Prendergast EN, Holzapfel M, Mueller JJ, Leitao MM, Gunderson CC, Moore KN, Erickson BK, Leath CA, Diaz Moore ES, Cohen JG, Walsh CS. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. Gynecol Oncol. 2017 Feb; 144(2):274-278.
    View in: PubMed
    Score: 0.092
  5. Diaz ES, Walts AE, Karlan BY, Walsh CS. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. Gynecol Oncol. 2013 Dec; 131(3):541-5.
    View in: PubMed
    Score: 0.074
  6. Walsh CS, Karlan BY. Contemporary progress in ovarian cancer screening. Curr Oncol Rep. 2007 Nov; 9(6):485-93.
    View in: PubMed
    Score: 0.049
  7. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005 Oct; 106(4):693-9.
    View in: PubMed
    Score: 0.042
  8. Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. Am Surg. 2020 Oct; 86(10):1243-1247.
    View in: PubMed
    Score: 0.030
  9. Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 10 20; 38(30):3468-3493.
    View in: PubMed
    Score: 0.030
  10. Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, Soslow RA, Leitao MM. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.
    View in: PubMed
    Score: 0.022
  11. Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, de Fazio A, Mitchell G, Fereday S, Bolton KL, Gourley C, Michie C, Karlan B, Lester J, Walsh C, Cass I, Olsson H, Gore M, Benitez JJ, Garcia MJ, Andrulis I, Mulligan AM, Glendon G, Blanco I, Lazaro C, Whittemore AS, McGuire V, Sieh W, Montagna M, Alducci E, Sadetzki S, Chetrit A, Kwong A, Kjaer SK, Jensen A, Høgdall E, Neuhausen S, Nussbaum R, Daly M, Greene MH, Mai PL, Loud JT, Moysich K, Toland AE, Lambrechts D, Ellis S, Frost D, Brenton JD, Tischkowitz M, Easton DF, Antoniou A, Chenevix-Trench G, Gayther SA, Bowtell D, Pharoah PD. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res. 2015 Feb 01; 21(3):652-7.
    View in: PubMed
    Score: 0.020
  12. Moschiano EJ, Barbuto DA, Walsh C, Singh K, Euscher ED, Roma AA, Ali-Fehmi R, Frauenhoffer EE, Montiel DP, Kim I, Djordjevic B, Malpica A, Hong SR, Silva EG. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014 May; 33(3):268-73.
    View in: PubMed
    Score: 0.019
  13. Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014 Feb; 132(2):334-42.
    View in: PubMed
    Score: 0.019
  14. Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013 Dec; 131(3):609-12.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)